Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Quarterly Earnings Results

Posted by Stanley Muller on Nov 7th, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) issued its earnings results on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03), FiscalAI reports.

Here are the key takeaways from Corvus Pharmaceuticals’ conference call:

Corvus ended September with $202.9 million in cash, cash equivalents and marketable securities, which management says should fund operations into the second quarter of 2028. Third-quarter R&D expense more than doubled year over year to $17.8 million, and net loss rose to $20.3 million.
The phase III trial of soquelitinib in relapsed/refractory PTCL is enrolling as planned, with an event-driven futility review expected in Q1 2027 and top-line results anticipated before year-end 2027. If the independent committee recommends continuing, Corvus says it will disclose the decision but not interim safety or efficacy data.
Corvus expects top-line results from its phase II atopic dermatitis trial in Q3 2027; enrollment is on track, and the company sees potential to start phase III in 2028 if results are successful. Partner Angel expects preliminary data from its first cohort in March 2027, with second-cohort data potentially in the second half of the year.
The company is expanding soquelitinib development into hidradenitis suppurativa and asthma: HS enrollment is ahead of plan, with results potentially in the first half of 2027, while the asthma trial is planned to start in Q1 2027. These programs remain early-stage, and the company’s expectations are based on its view of the drug’s mechanism.
Initial results from three adults in the NIAID-led ALPS study showed all patients discontinued background medications, with improvements in disease measures and no grade 3 or 4 adverse events reported after a year of treatment. Corvus plans to take over the IND and discuss expanding the study to additional sites and pediatric patients; the small patient group makes the findings preliminary.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $10.54 on Friday. The firm has a market cap of $886.62 million, a PE ratio of -14.84 and a beta of 1.57. Corvus Pharmaceuticals has a one year low of $6.39 and a one year high of $26.95. The firm’s fifty day moving average is $11.50 and its two-hundred day moving average is $14.36.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on CRVS shares. LADENBURG THALM/SH SH upgraded Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. Mizuho set a $27.00 price target on Corvus Pharmaceuticals in a research report on Thursday, October 29th. Finally, Wall Street Zen downgraded Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.83.

Check Out Our Latest Research Report on Corvus Pharmaceuticals

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.